PMID- 30159775
OWN - NLM
STAT- MEDLINE
DCOM- 20191001
LR  - 20191001
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 38
IP  - 11
DP  - 2018 Nov
TI  - Proton pump inhibitors' use and risk of hip fracture: a systematic review and 
      meta-analysis.
PG  - 1999-2014
LID - 10.1007/s00296-018-4142-x [doi]
AB  - In the last decade, epidemiological studies presented inconsistent findings 
      concerning the proton pump inhibitors (PPI) use and the risk of hip fracture. So, 
      this systematic review and meta-analysis were performed with the aim to quantify 
      the risk of hip fracture associated with PPI use. PubMed((R)) and Cochrane Central 
      databases were searched from inception to January 2018. The quality of included 
      studies in meta-analysis was assessed using Newcastle-Ottawa scale. Primary 
      outcome of this study was to assess the risk of hip fracture among PPI user. 
      Secondary outcomes include subgroup analysis based on study design, study 
      quality, duration of PPI use, calcium intake, and geographical region. 
      Sensitivity analysis was also performed. Review Manager (RevMan) was used to 
      perform statistical analysis. This meta-analysis was based on seventeen studies. 
      Pooled risk ratio showed a statistically significant association between PPI use 
      and hip fracture risk (RR 1.26 [95% CI 1.17-1.35], p < 0.00001). Subgroup 
      analysis, based on the study design, showed a highly significant association 
      between PPI use and risk of hip fracture (p < 0.0001). The risk of hip fracture 
      persisted even when stratified by calcium adjustment and the duration of PPI use 
      (p < 0.0001). This meta-analysis suggests that PPI user have a 26% increased risk 
      of hip fracture as compared to non-PPI user. Physicians should take caution in 
      prescribing PPI to patients who are at increased risk of hip fracture.
FAU - Hussain, Salman
AU  - Hussain S
AUID- ORCID: 0000-0002-1691-8428
AD  - Department of Pharmaceutical Medicine (Division of Pharmacology), School of 
      Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
FAU - Siddiqui, Ali Nasir
AU  - Siddiqui AN
AUID- ORCID: 0000-0001-9813-2447
AD  - Department of Pharmaceutical Medicine (Division of Pharmacology), School of 
      Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
FAU - Habib, Anwar
AU  - Habib A
AUID- ORCID: 0000-0003-3589-8810
AD  - Department of Medicine, Hamdard Institute of Medical Sciences and Research, Jamia 
      Hamdard, New Delhi, India.
FAU - Hussain, Md Sarfaraj
AU  - Hussain MS
AUID- ORCID: 0000-0003-4555-5643
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Misurata University, Misurata, 
      Libya.
FAU - Najmi, Abul Kalam
AU  - Najmi AK
AUID- ORCID: 0000-0002-9299-414X
AD  - Department of Pharmacology, School of Pharmaceutical Education and Research, 
      Jamia Hamdard, New Delhi, 110062, India. aknajmi@jamiahamdard.ac.in.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20180829
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Clinical Decision-Making
MH  - Female
MH  - Hip Fractures/*chemically induced/diagnosis/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Risk Assessment
MH  - Risk Factors
OTO - NOTNLM
OT  - Bone
OT  - Hip fracture
OT  - Meta-analysis
OT  - Osteoporosis
OT  - Proton pump inhibitors
OT  - Systematic review
EDAT- 2018/08/31 06:00
MHDA- 2019/10/02 06:00
CRDT- 2018/08/31 06:00
PHST- 2018/07/08 00:00 [received]
PHST- 2018/08/20 00:00 [accepted]
PHST- 2018/08/31 06:00 [pubmed]
PHST- 2019/10/02 06:00 [medline]
PHST- 2018/08/31 06:00 [entrez]
AID - 10.1007/s00296-018-4142-x [pii]
AID - 10.1007/s00296-018-4142-x [doi]
PST - ppublish
SO  - Rheumatol Int. 2018 Nov;38(11):1999-2014. doi: 10.1007/s00296-018-4142-x. Epub 
      2018 Aug 29.